Forian (FORA)
Market Price (5/13/2026): $2.16 | Market Cap: $67.0 MilSector: Health Care | Industry: Health Care Technology
Forian (FORA)
Market Price (5/13/2026): $2.16Market Cap: $67.0 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -47% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 50% Megatrend and thematic driversMegatrends include Cloud Computing, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Health Data Analytics, Show more. | Weak multi-year price returns2Y Excs Rtn is -60%, 3Y Excs Rtn is -98% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8.2% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 23x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.5% Key risksFORA key risks include [1] its persistent unprofitability with an uncertain path to positive earnings and [2] a significant revenue dependence on the successful renewal of key customer contracts, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -47% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 50% |
| Megatrend and thematic driversMegatrends include Cloud Computing, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Health Data Analytics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -60%, 3Y Excs Rtn is -98% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8.2% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 23x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.5% |
| Key risksFORA key risks include [1] its persistent unprofitability with an uncertain path to positive earnings and [2] a significant revenue dependence on the successful renewal of key customer contracts, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Definitive Merger Agreement for $2.17 per Share: On April 3, 2026, Forian announced it entered a definitive merger agreement to be acquired in an all-cash transaction for $2.17 per share. This offer represented a premium of approximately 22.6% to Forian's unaffected closing price as of August 22, 2025, providing a significant upward catalyst for the stock within the specified period.
2. Strong Insider Commitment to Privatization: A consortium of investors, led by CEO Max Wygod, increased its beneficial ownership to 70.5% of Forian's common stock as of April 15, 2026, through a Contribution Agreement. This substantial insider control and active participation in the take-private transaction signal a high likelihood of the merger closing in the second quarter of 2026, which bolstered investor confidence and supported the stock's movement towards the offer price.
Show more
Stock Movement Drivers
Fundamental Drivers
The 2.9% change in FORA stock from 1/31/2026 to 5/12/2026 was primarily driven by a 7.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.10 | 2.16 | 2.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28 | 30 | 7.6% |
| P/S Multiple | 2.3 | 2.2 | -4.6% |
| Shares Outstanding (Mil) | 31 | 31 | 0.1% |
| Cumulative Contribution | 2.9% |
Market Drivers
1/31/2026 to 5/12/2026| Return | Correlation | |
|---|---|---|
| FORA | 2.9% | |
| Market (SPY) | 7.0% | -3.5% |
| Sector (XLV) | -5.4% | -10.2% |
Fundamental Drivers
The -3.6% change in FORA stock from 10/31/2025 to 5/12/2026 was primarily driven by a -20.6% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.24 | 2.16 | -3.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 25 | 30 | 20.9% |
| P/S Multiple | 2.8 | 2.2 | -20.6% |
| Shares Outstanding (Mil) | 31 | 31 | 0.5% |
| Cumulative Contribution | -3.6% |
Market Drivers
10/31/2025 to 5/12/2026| Return | Correlation | |
|---|---|---|
| FORA | -3.6% | |
| Market (SPY) | 8.8% | -2.9% |
| Sector (XLV) | 2.0% | -3.4% |
Fundamental Drivers
The 6.9% change in FORA stock from 4/30/2025 to 5/12/2026 was primarily driven by a 50.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.02 | 2.16 | 6.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20 | 30 | 50.1% |
| P/S Multiple | 3.1 | 2.2 | -28.9% |
| Shares Outstanding (Mil) | 31 | 31 | 0.2% |
| Cumulative Contribution | 6.9% |
Market Drivers
4/30/2025 to 5/12/2026| Return | Correlation | |
|---|---|---|
| FORA | 6.9% | |
| Market (SPY) | 34.6% | 12.7% |
| Sector (XLV) | 5.7% | 2.5% |
Fundamental Drivers
The -18.8% change in FORA stock from 4/30/2023 to 5/12/2026 was primarily driven by a -57.5% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.66 | 2.16 | -18.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 16 | 30 | 84.3% |
| P/S Multiple | 5.2 | 2.2 | -57.5% |
| Shares Outstanding (Mil) | 32 | 31 | 3.7% |
| Cumulative Contribution | -18.8% |
Market Drivers
4/30/2023 to 5/12/2026| Return | Correlation | |
|---|---|---|
| FORA | -18.8% | |
| Market (SPY) | 84.4% | 9.4% |
| Sector (XLV) | 14.8% | 8.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| FORA Return | -61% | -70% | 7% | -30% | 3% | 2% | -91% |
| Peers Return | -2% | -48% | 4% | -26% | -19% | -40% | -81% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| FORA Win Rate | 40% | 42% | 58% | 33% | 50% | 40% | |
| Peers Win Rate | 47% | 35% | 48% | 40% | 42% | 24% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| FORA Max Drawdown | -66% | -76% | -22% | -32% | -15% | -4% | |
| Peers Max Drawdown | -20% | -58% | -25% | -36% | -34% | -46% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IQV, VEEV, DH, HCAT, CERT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/12/2026 (YTD)
How Low Can It Go
| Event | FORA | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -25.6% | -9.5% |
| % Gain to Breakeven | 34.4% | 10.5% |
| Time to Breakeven | 104 days | 24 days |
In The Past
Forian's stock fell -8.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 9.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | FORA | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -25.6% | -9.5% |
| % Gain to Breakeven | 34.4% | 10.5% |
| Time to Breakeven | 104 days | 24 days |
In The Past
Forian's stock fell -8.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 9.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Forian (FORA)
AI Analysis | Feedback
Here are 1-2 brief analogies for Forian (FORA):
It's like SAP for the cannabis industry, managing everything from 'seed-to-sale' operations to regulatory compliance.
It's like a specialized Palantir for regulated sectors like cannabis and healthcare, providing critical data analytics and traceability for businesses and government.
AI Analysis | Feedback
- BioTrack: A vertically integrated software solution for cannabis businesses, covering point of sale, manufacturing, delivery, and cultivation.
- Cannalytics: A Software as a Service (SaaS) based analytics solution providing clients with a presentation of business performance.
- BioTrack seed-to-sale compliance traceability platform: A platform used to manage the tracking and tracing of various cannabis products from cultivation to sale.
- BioTrack State Traceability & Enforcement Monitoring System (STEMS): A module that provides cannabis program management and ensures transparency and accountability throughout the cannabis supply chain for regulatory agencies.
- Security Monitoring Services: Services offered for security monitoring.
- Web Marketing Services: Services provided for web marketing.
AI Analysis | Feedback
Forian Inc. sells primarily to other companies and government agencies (B2B and B2G). The company's major customers fall into the following categories:
- Healthcare companies
- Cannabis companies, including:
- Dispensaries
- Cultivators
- Manufacturers
- Distributors
- Government agencies, specifically cannabis regulatory agencies
AI Analysis | Feedback
Max Wygod, CEO & Executive Chair
Max Wygod is a healthcare executive and investor with experience in investing, acquiring, and divesting public and private growth companies at the intersection of healthcare and information technology. He leads the investment strategy for Wygod & Co. LLC, a virtual family office dedicated to private and public investments in the healthcare industry. His father, Marty Wygod, successfully led seven public companies, primarily in early stages, with an appreciation in value of over $15 billion for public investors. Marty Wygod led the sale of WebMD to a KKR portfolio company for $2.8 billion. Max Wygod previously served as a Vice President of Business Development at WebMD Health, where he participated in facilitating its sale to KKR. Marty Wygod also founded Medco Containment Services Inc., which was acquired by Merck & Company for approximately $6 billion.
Mike Vesey, Chief Financial Officer
Michael Vesey was appointed Chief Financial Officer of Forian Inc. effective September 2, 2021. Prior to joining Forian, he served as the Chief Financial Officer of Wayside Technology Group, Inc. (Nasdaq: WSTG), a provider of cybersecurity, software, and technology solutions, from 2016 to 2021. During his five-year tenure with Wayside, Vesey led multiple acquisitions that helped facilitate the organization's shift to a cloud marketplace. Before Wayside, he spent nine years at Majesco Entertainment Company, where he progressed from Chief Accounting Officer to Chief Financial Officer, serving as CFO from 2011 to 2016.
Adam Dublin, Co-founder & Chief Strategy Officer
Adam Dublin is a co-founder of Forian Inc.
Paul Reuscher, Chief Commercial Officer
Paul Reuscher serves as the Chief Commercial Officer for Forian Inc.
Caroline McGrail, General Counsel & Secretary
Caroline McGrail holds the position of General Counsel & Secretary at Forian Inc.
AI Analysis | Feedback
The key risks to Forian's business are:
-
Regulatory Risk, particularly within the Cannabis Industry: Forian's core offerings, such as BioTrack and STEMS, are deeply integrated with compliance and traceability requirements in the cannabis sector, which is subject to complex and evolving state and federal regulations. Changes in these laws, increased regulatory scrutiny, or shifts in how regulatory bodies mandate traceability systems could significantly impact Forian's business operations and demand for its products. The legal ambiguity of cannabis at the federal level also introduces inherent market uncertainty.
-
Intense Competition: Forian operates in competitive markets, including healthcare software, cannabis management solutions, and data analytics. The presence of numerous companies offering similar seed-to-sale tracking, point-of-sale systems, and analytics platforms could lead to pricing pressures, potential loss of market share, and the necessity for continuous and costly innovation to maintain a competitive edge.
-
Data Security and Privacy Concerns: Given that Forian manages proprietary data, delivers data-driven insights, and handles sensitive operational, clinical, and financial information for its healthcare, cannabis, and government clients, it faces significant risks related to data security and privacy. A data breach, cyber-attack, or failure to comply with stringent data privacy regulations (such as HIPAA in healthcare or specific cannabis data privacy laws) could result in substantial financial penalties, severe reputational damage, and a significant loss of customer trust.
AI Analysis | Feedback
nullAI Analysis | Feedback
Forian Inc. (FORA) has strategically shifted its focus from the cannabis industry to concentrate primarily on healthcare information, analytics, and data science solutions. The company divested its cannabis software subsidiary, BioTrack (which included Cannalytics), to Alleaves, Inc. in February 2023. Forian now retains a license to certain cannabinoid-based data to enhance its healthcare information offerings. Forian's main products and services are now within the healthcare analytics market, which includes clinical analytics, commercial analytics, and technology platform solutions. The global market for healthcare analytics was approximately $19 billion in 2019 and was projected to grow to an estimated $50.5 billion by 2024.AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Forian (FORA)
Forian Inc. is strategically focused on its healthcare and life sciences segments following the divestiture of its cannabis industry software solutions in February 2023. Over the next 2-3 years, the company's revenue growth is expected to be driven by the following factors:
-
Kyber Data Science Acquisition and Integration: The acquisition and ongoing integration of Kyber Data Science are significant growth drivers. This acquisition expands Forian's analytical capabilities and market reach, including into financial services customers, while also strengthening its data science and predictive analytics offerings. The Kyber acquisition contributed approximately $2 million (43%) to the Q3 2025 revenue growth and $5.6 million year-to-date. Forian anticipates 39%-49% revenue growth in 2025, largely driven by the expansion of health data analytics through Kyber integration.
-
Expansion in Health Economics and Outcomes Research (HEOR) Projects: A key driver is the continued expansion in health economics and outcomes research (HEOR) projects. Forian's robust data factory, which aggregates, integrates, normalizes, and cleanses diverse data from multiple sources like medical and pharmacy claims, electronic medical records (EMR), laboratory data, and social determinants of health, is crucial for helping clients answer complex questions regarding treatment patterns, patient outcomes, and market dynamics.
-
New Customer Acquisition and Deepening Existing Relationships in Healthcare: Forian is focused on expanding its client base and deepening its relationships within the healthcare sector. The company's Q4 2023 earnings indicated revenue growth from both new customers and increased engagement with existing clients in its continuing healthcare operations. The integration of Kyber Data Science is also expected to contribute to an increased client base and stronger existing relationships.
-
Strategic Investments in Information Products and Data Assets: Ongoing strategic investments in information products and data assets within the healthcare business are expected to fuel future growth. This includes further investments in data, such as the acquisition of a database covering 65 million covered lives, to enhance capabilities in health economics and outcomes research.
-
Advancement of Data Integration and Proprietary Platforms: Forian plans to advance its data integration capabilities and further develop its proprietary platforms, including the Kyber platform. The company's data factory is considered a critical differentiator, continuously integrating and enriching data from various sources to provide a unified view of the healthcare ecosystem, which enhances client decision-making.
AI Analysis | Feedback
Share Repurchases
- Forian Inc. repurchased 1,604,676 shares of its common stock in a privately negotiated transaction on October 3, 2023, for an aggregate purchase price of approximately $3.45 million.
- The repurchased shares were subsequently cancelled and retired.
Share Issuance
- Forian Inc. had approximately 31 million shares outstanding in Q3 2025.
- The number of shares outstanding has shown minor fluctuations, with a slight decrease of 0.1% from the prior quarter in Q3 2025 and a 0.30% increase over one year as of a recent report.
Outbound Investments
- In November 2024, Forian Inc. acquired Kyber Data Science LLC from TD Cowen.
- Forian completed the divestiture of BioTrack to refocus its business on core healthcare and life sciences activities.
Capital Expenditures
- Forian Inc. reported investing $0 in capital expenditures in Q3 2024.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Forian Earnings Notes | 12/16/2025 | |
| Is Forian Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to FORA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.62 |
| Mkt Cap | 0.5 |
| Rev LTM | 361 |
| Op Inc LTM | 3 |
| FCF LTM | 45 |
| FCF 3Y Avg | 52 |
| CFO LTM | 65 |
| CFO 3Y Avg | 69 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.9% |
| Rev Chg 3Y Avg | 5.8% |
| Rev Chg Q | 4.6% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Inc Chg LTM | 29.6% |
| Op Inc Chg 3Y Avg | 25.6% |
| Op Mgn LTM | -2.8% |
| Op Mgn 3Y Avg | -3.2% |
| QoQ Delta Op Mgn LTM | 0.8% |
| CFO/Rev LTM | 16.4% |
| CFO/Rev 3Y Avg | 18.3% |
| FCF/Rev LTM | 12.0% |
| FCF/Rev 3Y Avg | 14.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.5 |
| P/S | 1.8 |
| P/Op Inc | 4.5 |
| P/EBIT | 6.1 |
| P/E | -0.5 |
| P/CFO | 9.9 |
| Total Yield | -3.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.9% |
| D/E | 0.5 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.8% |
| 3M Rtn | -21.0% |
| 6M Rtn | -42.8% |
| 12M Rtn | -46.0% |
| 3Y Rtn | -42.3% |
| 1M Excs Rtn | -6.7% |
| 3M Excs Rtn | -27.6% |
| 6M Excs Rtn | -53.6% |
| 12M Excs Rtn | -75.9% |
| 3Y Excs Rtn | -127.6% |
Price Behavior
| Market Price | $2.16 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 03/03/2021 | |
| Distance from 52W High | -13.3% | |
| 50 Days | 200 Days | |
| DMA Price | $2.11 | $2.12 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 2.2% | 1.8% |
| 3M | 1YR | |
| Volatility | 10.4% | 51.4% |
| Downside Capture | -6.79 | 37.74 |
| Upside Capture | 7.79 | 36.27 |
| Correlation (SPY) | -4.3% | 11.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.07 | 0.02 | -0.02 | 0.02 | 0.54 | 0.40 |
| Up Beta | -0.15 | -0.11 | -0.07 | -0.01 | 1.17 | 0.37 |
| Down Beta | 0.55 | 0.02 | -0.17 | -0.09 | 0.18 | 0.60 |
| Up Capture | 21% | 15% | 5% | -3% | 22% | 7% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 9 | 17 | 22 | 49 | 106 | 332 |
| Down Capture | -54% | -2% | 2% | 20% | 52% | 67% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 6 | 17 | 27 | 54 | 112 | 358 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FORA | |
|---|---|---|---|---|
| FORA | 8.7% | 51.5% | 0.33 | - |
| Sector ETF (XLV) | 11.9% | 15.5% | 0.53 | 1.3% |
| Equity (SPY) | 32.5% | 12.4% | 1.98 | 12.1% |
| Gold (GLD) | 41.3% | 26.9% | 1.26 | 1.5% |
| Commodities (DBC) | 50.3% | 18.5% | 2.06 | -0.7% |
| Real Estate (VNQ) | 12.8% | 13.5% | 0.65 | 4.8% |
| Bitcoin (BTCUSD) | -21.0% | 41.7% | -0.46 | -4.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FORA | |
|---|---|---|---|---|
| FORA | -28.9% | 71.6% | -0.18 | - |
| Sector ETF (XLV) | 5.1% | 14.6% | 0.17 | 10.9% |
| Equity (SPY) | 13.7% | 17.1% | 0.63 | 13.0% |
| Gold (GLD) | 21.0% | 17.9% | 0.95 | -0.3% |
| Commodities (DBC) | 11.4% | 19.4% | 0.47 | 4.0% |
| Real Estate (VNQ) | 3.9% | 18.8% | 0.11 | 12.4% |
| Bitcoin (BTCUSD) | 7.2% | 55.9% | 0.34 | 7.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FORA | |
|---|---|---|---|---|
| FORA | -21.4% | 74.4% | -0.30 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 10.4% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 12.0% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 0.1% |
| Commodities (DBC) | 8.4% | 17.9% | 0.39 | 3.3% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 10.7% |
| Bitcoin (BTCUSD) | 68.2% | 66.8% | 1.07 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/27/2026 | 0.5% | 4.4% | 4.4% |
| 11/14/2025 | 4.2% | 1.9% | 0.0% |
| 8/13/2025 | 1.6% | -0.5% | 18.4% |
| 5/14/2025 | 20.4% | 10.2% | 4.8% |
| 11/13/2024 | -0.5% | 0.5% | 0.0% |
| 8/14/2024 | -2.8% | -2.8% | -7.7% |
| 3/28/2024 | -13.9% | -11.7% | -19.7% |
| 11/9/2023 | 8.3% | 12.5% | 2.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 8 | 7 |
| # Negative | 7 | 8 | 9 |
| Median Positive | 4.2% | 7.8% | 4.4% |
| Median Negative | -3.3% | -6.9% | -17.5% |
| Max Positive | 20.4% | 12.8% | 38.4% |
| Max Negative | -13.9% | -15.9% | -44.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/27/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/11/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.